Innovation. Commercialisation. Access · Innovation. Commercialisation. Access AGENDA ANNOUNCED 40+ COUNTRIES 2 ... Jim Miller Vice President and ... Stephen Dunn Regional Director

10th annual

21 - 23 March 2017Suntec Singapore Convention& Exhibition Centre, Singapore

In conjunction with

www.terrapinn.com/bioasia

Innovation. Commercialisation. Access

AGENDA ANNOUNCED

40+ COUNTRIES

2SUMMITS

4WORKSHOPS

2SITE TOURS

http://www.terrapinn.com/bioasia

Contact Pinky Fadullon at (65) 6322 2738 or [email protected] to discuss your participation options

Our Story

Vice President, Xeraya Biologics

A GREAT PLACE TO MEET PEOPLE IN THE INDUSTRY, TO GET CONNECTED AND TO LEARN ABOUT THE CURRENT TRENDS IN THE MARKET.”

“

Asia’s biopharma industry has evolved from a manufacturing destination to a go-to market for clinical development and a hotbed of innovation. Asia contains some of the world’s hottest pharma and biopharmaceutical markets on the planet, including China and Indonesia. Are you making the most of the opportunity?

Welcome to BioPharma Asia 2017.

From humble beginnings as BioMedical Asia in 2008, BioPharma Asia has served over to 20,000 attendees over the last 9 years.A true one-stop shop for all things biopharma, our 2017 program will be our best yet. Our premium conference tracks will explore innovation in drug discovery and development, commercial partnership strategies, clinical trial design and regulatory affairs, commercialization & marketing, manufacturing, supply chain and more. We’ll also be featuring our most comprehensive biotech pitching opportunities ever, in our dedicated Biotech Innovation track offering you the chance to hear from the latest innovators.

Visionary keynotes will lay the foundations for two days of intensive learning, discussion and networking. Leading C-Level executives will share case studies from across the world, ensuring you can learn from the best of the best, then you can spend time debating with them during the small-group roundtable sessions, so you have time to foster relationships and make new business contacts.

If you want to meet the key influencers and the true innovators of Asia’s biopharmaceutical industry, then this is the perfect platform.

Limited speaking slots available! Contact Emily Chong at (65) 6322 2339 [email protected] for speaking opportunities.

PRE-CONFERENCE PROGRAM TUESDAY, 21ST MARCH 2017

Agenda at a Glance

Research/Academic Site TourManufacturing Technical SymposiumOrphan Drug Congress Asia

Biotech Bootcamp Part 1

Biotech Bootcamp Part 2

Pre-Event Networking Drinks Reception

DAY TWO THURSDAY, 23RD MARCH 2017

Keynote Plenary: Local Biotech & Pharma Focus

Exhibition Visit & Networking Refreshments

Exhibition Visit & Networking Lunch


Close of BioPharma Asia 2017

BIOTECH INNOVATION

Antibody Drug Conjugates & Derivatives

MEDICAL AFFAIRS

Stakeholder Engagement

CLINICAL TRIALS

Clinical Innovations

BIOLOGICS MANUFACTURING

Continuous Processing

Vaccines for Infectious Diseases Evidence & Decision Making Clinical Supply Quality & Safety

Stem Cells, Biomarkers & Gene Therapy Safety & Compliance Clinical Operations Analytical Development

Supply Chain Technical SymposiumManufacturing/Packaging Site Tour

DAY ONE WEDNESDAY, 22ND MARCH 2017

CLINICAL TRIALS

Clinical Development

Regulatory Affairs

SUPPLY CHAIN

Regulation

Technology

BIOTECH INNOVATION

Immuno-oncology

Therapeutic vaccines

Keynote Plenary: Digital Transformation in BioPharma


Exhibition Visit & Networking Lunch


Roundtable Discussion Session

Plenary: Asia Spotlight: Credibility & Patient Centricity

Networking Drinks Reception

MARKET ACCESS

Pricing & Reimbursement

Country Spotlights


Next-Generation Biologics Products

Process Design & Development

BioPharma Asia Marketing Summit

Carl FirthChief Executive Officer

Aslan Pharmaceuticals (Singapore)

Silviu ItescuCEO and Managing Director

Mesoblast, Australia

Weng Si HoExecutive Director – Biomedical Sciences

Singapore Economic Development Board

Jun WangFounder, Executive DirectorBeijing Genome Institute

(BGI), (China)

Raman SrinivasanVice President andHead of Operations

Biocon, (Malaysia)

Shao Siong ChuaHead of ManufacturingBaxalta (Singapore)

Steven LeeGlobal Head,

Technical Operations Dr Reddy’s Laboratories,

(India)

Frederik AslundPatent Examiner

European Patent Office (Austria)

Sean WuXiong CaoVice President, Global Business Development

Simcere Pharmaceutical Group, (China)

Yariv Hefez VP Strategic Development,

Business Development, Portfolio Management and

Partnering (Biosimilar) Merck (Switzerland)

Manjunath RamaraoGlobal Director & Head,

Disease Sciences & Technology

Bristol Myers Squibb, (India)

Peter HoangSenior Vice President,

Business Development and Strategy

Bellicum, (USA)

Ajay GautamExecutive Director & Head,

Asia Pacific & Emerging Markets, Scientific Partnering

and Alliances Astra Zeneca (China)

Rubby ChawlaFounder and President

Indian Patients Society for Primary

Immunodeficiency, (India)

Jim Miller Vice President and Head Bioogics Drug Substance

Manufacturing Genentech, Roche (USA)

William ClaxtonDirector and Co-Founder Asia-Pacific Alliance

of Rare Disease Organization (APARDO)

Paolo RampichiniHead, Supply Chain Asia

PacificRoche (Singapore)

Stephen DunnRegional Director of Investigations, APAC

Sanofi Aventis, (Singapore)

Abhishek BhagatRegional Medical Director,

Consumer HealthMerck Pte Ltd (Singapore)

James GarnerChief Executive OfficerNovogen, (Australia)

Eddie TamHead of Scientific andClinical Procurement,Asia Pacific & Japan

Sanofi, (China)

Pierre WinnepennickxPresident, ISPE Asia Pacific

Dimiter DimitrovSenior Investigator, Head of Protein Interactions Section

NIH, (USA)

Satish JindalCEO

Allied-Bristol Life Sciences (USA)

Koichi MiyazakiSenior Director, Regulatory

Affairs Group, Asia Development Department,

R&D DivisionDaiichi-Sankyo (Japan)

Carlos PereiraSite Head, ManufacturingNovartis, (Singapore)

Churn-Shiouh Gau Chief Executive Director

Center for Drug Evaluation (Taiwan)

Hugh DavisVice President, Head, Biologics

Clinical Pharmacology and China Biologics Leader,

Biotechnology CoEJanssen, (USA)

Alan Bollard Executive Director

Asia-Pacific Economic Corporation (APEC)

Secretariat (Singapore)

Peter SenterVice President, ChemistrySeattle Genetics, (USA)

Nick EdeExecutive Director

Imugene (Australia)

Yee Leong TeohCEO

Singapore Clinical Research Institute,

(Singapore)

Stewart GearySenior Vice President, Chief

Medical Officer, General Manager, Corporate Medical

Affairs HeadquarterEisai Co. Ltd (Japan)

Shubhadeep SinhaAssociate VP and Head,

Clinical Affairs, Medical Affairs and Pharmacovigilance,

Global Operations Hetero Group, (India)

Donnie McgrathVice President,

Executive Director Bristol Myers Squibb,

(USA)

Paul KimCEO

Medivate Partners, (Korea)

Stefan HartDirector, New Venture

J&J Innovation Center, (Singapore)

Lucas ChanSite Head, Manufacturing

King’s College Hospital Clinical Research Facility,

(UK)

Abrar MirFounder and

Managing Partner Quadria Capital,

(Singapore)

Shailendra BajpaiRegional Medical Director,

Diabetes Asia Sanofi- Aventis,

(Singapore)

Badri RengarajanPresident

International Pemphigus & Pemphigoid Foundation,

(USA)

Oliver NicolaiSenior Manager, Logistics and

Supply chain APAC Celgene, (Singapore)

Arun MaseehVice President, Research, Cluster Head, Innovation

Cadila Pharmaceuticals, (India)

Roman IvanovR&D Director

BIOCAD, (Russia)

Peter CulpepperCFO, COO Provectus

Biopharmaceuticals, (USA)

Yoshiya OdaPresident, Biomarkers and

Personalised Medicine Eisai Inc, (USA)

Ariane M. DavisonDirector of CommercialisationPacific Gene Tech, (China)

Jeffrey ChuaProcurement TechOps

Cluster Lead Novartis, (Singapore)

Brian MinVice President,

Biosimilars Development Samsung Biologics,

(South Korea)

Liang SchweizerHead of Asian Cancer

Research for AP Research Sanofi, (China)

Bobby GeorgeVP and Head of

Regulatory Affairs Reliance Life sciences,

(India)

John LimExecutive Director, Duke-NUS

Centre of Regulatory Excellence (CoRE),

(Singapore)

G S ReddySenior Vice President

Indian Immunologicals Limited, (India)

Nikhil SinglaAssociate Director, Vaccine

R&D ProgramInternational AIDS

Vaccines Initiative (IAVI), (India)

Maggie LimClinical Compliance Director,

Asia Pac, Japan and EM GlaxoSmithKline,

(Singapore)

Contact Emily Chong at (65) 6322 2339 [email protected] for speaking opportunities.Past Speakers

8.00

PRE-CONFERENCE PROGRAM

Registration

3-day conference pass holders can select 1 morning and 1 afternoon session or one of our full-day pre-event summits. The choice is yours!

PRE-CONFERENCE DAY TUESDAY, 21ST MARCH 2017 DAY 1 WEDNESDAY, 22ND MARCH 2017 1/4

WORKSHOP 1:BIOTECH BOOTCAMP

PART 1

WORKSHOP 3: BIOTECH BOOTCAMP

PART 2

Financing a cure: Getting your business plan and pitch book right, for successful fundraising.

In part 1, we explore how to increase your chances of fundraising success, including:

• Plan for success: What makes a strong business plan?

• How to value your biotech start-up

• Developing your story• Maximising your social media

presence • Protecting your IP• Making yourself stand out

from the crowd: How can you position

Primer in successful partnership management: Licensing, partnerships and strategic alliance management

In part 2, we talk partnerships and growth strategy

• What should you be looking for in your partners and how can you make your business more attractive to them?

• What makes a successful partnership?

• When do you build a board?• How do you meet your buy-

side customers • Getting your pitching strategy

right

WORKSHOP 2:MANUFACTURING

TECHNICAL SYMPOSIUM

SITE TOUR 2:MANUFACTURING/PACKAGING SITE

This workshop focuses on protein aggregation & characterization methods in downstream purification,, with issues including:

• Understanding protein aggregation mechanisms

• Identifying the key stages in protein characterization

• Exploring available downstream & purification techniques and how they impact output and efficiency

Stay tuned for details of ourexciting 2017 site tours.

SITE TOUR 1:EXPERIMENTAL

THERAPEUTICS CENTER, A*STAR

WORKSHOP 4:SUPPLY CHAIN TECHNICAL

SYMPOSIUM

Witness drug discovery capabilities in Asia by joining us at a site tour to Experimental Therapeutics Center (ETC), a member of Agency of Science, Technology & Research (A*STAR). From assay development, high throughput screening, medicinal chemistry and ADME/toxicology, scientists from ETC show you how Singapore translate early stage discoveries towards proof-of-concept and into diagnostic and research tools.

From risk management to supply chain security, this workshop provides you with case studies showing how to improve your supply chain efficiency. Key areas of discussion include:

• Compare and contrast real time track & trace methods

• How packaging facilities and solutions can impact supply chain efficiency

• The impact of emerging technologies

• Understand cross-Asia regulations and how you can remain compliant

BIOPHARMA ASIA MARKETING SUMMIT

From innovations in digital pharma marketing, to mobile patient engagement, to getting patient experience right, marketing strategies have never been more important to your biopharma business.

Join this one-day summit as our guest speakers explore innovations in healthcare marketing, including :

• Putting customer experience firmly on your biopharma agenda

• Getting multichannel marketing right

• How digital is enhancing patient experience

• New tools in patient recruitment

• Integrating digital marketing into your marketing strategy

• Making big data work for your marketing

• Going social: How can you effectively use social media in pharma marketing?

ORPHAN DRUGCONGRESS ASIA

Join governments, regulators, patient groups and orphan drug manufacturers at the one-day Orphan Drug Congress Asia as we plot the pathway to ensuring rare disease patients get proper medical care in Asia.

Key topics for discussion include:

• ASEAN Harmonization: How can we get there?

• If it’s good for them, it’s good for us: Reciprocal approval potential for orphan drugs in Asia

• The price is right: Pricing & reimbursement strategies and their impact on government budgets

• Trailblazers: Meet the countries who are supporting orphan drug access for their citizens and hear how they are doing it

• Getting there early: Early diagnosis potential through newborn screening

9.00

2.00

1.00 LUNCH & NETWORKING SESSION

7.00 END OF PRE-CONERENCE DAY

5.00 PRE-EVENT NETWORKING RECEPTIONJOIN US FOR A DRINK ON THE EVE OF THE CONFERENCE & EXHIBITION, AND GET A HEADSTART ON YOUR NETWORKING.

BIOTECHINNOVATION

IMMUNO-ONCOLOGY

This exciting new addition to BioPharma Asia 2017 will see 40 of Asia’s most exciting and

innovative biotechs offering 10-minute insights into their products, pipelines and their

pathway to commercialization.

Company presentation-ImugeneEliminating gastric cancer in Asia with B cell peptide immunotherapy – clinical update

Nick Ede, CTO, Imugene, Australia

Company presentation

From brand planning to drug pricing and reimbursement, market access remains a

major challenge for pharma companies. Learn from these speakers on how to get your products to the patients that need them, at the right price.

PANEL DISCUSSIONAsia’s market access landscape: Understanding the perspectives of payers, healthcare policy makers, pharma and patients• Exploring strategies to satisfy

healthcare needs by working closely with pharma, policy makers and payers

• Understanding key considerations and priorities from the payers’ perspective

• Formulating an efficient communication channel for building a sustainable healthcare environment

From clinical development, operations and supply to

regulatory affairs, explore the latest innovations and strategies

for getting your clinical trials right.

Key considerations in designing clinical trials protocols for pan-Asia clinical studies• Understanding key

opportunities in conducting clinical trials in Asia

• Discovering key preferred countries in conducting trials from pre-clinical, early phase to patient safety and consent

• Strategies for navigating Asia’s fragmented regulatory landscape

• Where are the next clinical trial hotspots in Asia?

Explore best practice strategies for your manufacturing activities

including process design, development & implementation, and the manufacturing of high quality emerging therapeutic

products

Keeping up with the production demands of an evolving portfolio in Asia• Understanding the

challenges associated with the biomanufacturing of an evolving portfolio

• Balancing flexibility, scalability and cost of manufacturing of emerging biological products

• Case study on manufacturing of immuno-oncology products

Major themes for this track include harmonization of Asia’s pharma supply chain regulation

and how new technology is making supply chain more transparent and efficient.

PANEL DISCUSSIONEstablishing coherent supply chain practices in Asia• Promoting free trade

movement to encourage trade and economic growth – where are we now and what’s next?

• Encouraging the alignment of regulations and standards to ensure hassle free movement of goods and people

• Overcoming IP, trade secret and safety regulation while opening borders

• Investigating the possibility of achieving coherency in border regulation and movement of goods with the Trans-Pacific Partnership Agreement.

MARKETACCESS

PRICING & REIMBURSEMENT

CLINICALTRIALS

CLINICAL DEVELOPMENT


NEXT GENERATION BIOLOGICS PRODUCTS

SUPPLY CHAIN

REGULATION

09:00

09:05

09:10

10:10

10:30

11:30

09:40

BIOPHARMA ASIA 2017 PRELIMINARY PROGRAM

DIGITAL TRANSFORMATION IN BIOPHARAMA

EXHIBITION VISIT & NETWORKING REFRESHMENTS

The future of medicine and how it impacts patients, pharma, physicians and regulators. In the digital age, with technology changing so rapidly, how can we make sure that we are prepared for the future? This exciting opening address for BioPharma Asia 2017 will explore the most exciting trends, ideas and technologies driving the future of our industry, including practical advice on how you can brace your business for the times ahead.

Redesigning healthcare system with artificial intelligence Some believe that artificial intelligence (AI) will lead to the end of human race, but there are also very clear benefits that AI could bring to the biopharma industry. Besides crunching data more efficiently and helping facilitate healing, AI can help in cutting clinical trial costs and time, thereby quickening the drug development process and getting much-needed drugs to market faster. Find out how AI can help companies to improve profit margins and deliver personalised treatments to patients in this exciting keynote session.

Blockchain meets Biopharma: How to prepare for the global data evolutionWhen you hear blockchain, you don’t necessarily think biopharmaceuticals. But the applications of blockchain can do so much more than digital currency. For example, it can help to increase the efficiency of the drug development process, by providing better security and transparency. It allows you to indelibly record medicinal and genomic data to combat counterfeit pharmaceutical production and protect intellectual property. That’s just a few applications. Join us as we uncover more and also consider some of the potential challenges that could be created, for example, around compliance and privacy.

Chairman’s opening remarks

Organiser’s welcome remarks

DAY 1 WEDNESDAY, 22ND MARCH 2017 2/4 DAY 1 WEDNESDAY, 22ND MARCH 2017 3/4






Pricing strategies and key considerations for bringing drugs from red to blue ocean markets in Asia• Risk assessment and

management in post market drugs

• Discover strategies for accessing this market, and navigating the fragmented regulatory framework in Asia

• Opportunities for working with country regulators to harmonise general, locally-adaptable guidelines improving drug access for patients

Will performance-based reimbursement be the future scheme in Asia?• Discovering benefits

of performance-based patient access schemes, as an alternative to current reimbursement plans in countries across Asia

• Understanding the challenges in implementing risk sharing schemes in Asia

• Identifying key practices required for long term viability of performance based drug reimbursement

• Is a strategy like this even possible when multiple country regulators are involved?

Tackling infrastructure, site selection and regulatory barriers to conduct successful pan-Asia clinical studies• Overcoming key regulatory

barriers to successfully conduct trials in emerging countries

• Exploring clinical site alternatives without compromising clinical data quality

• Qualifying trial sites to fulfil study requirements

Meeting the needs of patients: Practical advice for clinical developers planning pan-Asia trials

• Ensuring patient centricity of your clinical practices, through close communication with CROs, trial sites and partners

• Building the optimal communication methods with patients, for example, setting up apps or dedicated call centres

• Working with patient advocacy groups to better understand patient needs

From Phase 1 to 4: Quality management in Pan- Asia clinical trials• Developing and executing

quality audit from Phase 1 to 4 trials

• Cross functional teams working in top line study data communication

• Ensuring compliance and adherence to relevant regulations in Asia

Integrating hybrid options in biomanufacturing: Economic and operational implications• Discovering the best strategy

for integrating disposable solutions in existing facilities

• Realising the need for flexibility and scalability of hybrid manufacturing system in producing emerging therapeutic products

• Practical advice for integrating hybrid systems in your manufacturing operations

Next generation processes: What model works the best in Asia?Compare and contrast the available full scale processing technologies, and discover what works the best for manufacturing next generation therapeutic products in Asia.

CASE STUDY: JHL fully single use facility in China to manufacture biosimilars and monoclonal antibodiesHear first-hand how one company approached creating a fully single use facility for manufacturing of their products.

Handling challenges raised from parallel imports • Understanding impact of

grey market imports in drug pricing and motivation to innovate in Asia

• Exploring various pricing strategies to overcome parallel import of genuine products

• Exploring repackaging requirements for none authorised distributor prevent patient misinformation

Emerging compliance supply chain requirements in Asia • Establishing collaborative,

enterprise wide process for communicating compliance requirements with suppliers

• Ensuring clear assignment of compliance execution ownership for compliance adherence to local regulations

• Using constant engagement and linkage of individuals throughout an organization to prevent delay and potential loss of sales and product obsolescence

11:50

12:10

12:30

IMMUNO-ONCOLOGYPRICING &

REIMBURSEMENT CLINICAL DEVELOPMENT

NEXT GENERATION BIOLOGICS PRODUCTS

REGULATION







Exploring country-specific market access strategies• Besides pricing and

reimbursement, what are the other factors in consideration when accessing a new market in Asia?

• Understanding the role of patient groups and the importance of patient-centric approaches in defining your access strategy

• Overcoming regulatory hurdles: How can we handle the fragmented regulatory structures?

• Licensing by reciprocity in Asia: Is it even possible?

Country update:

Singapore

Country update:

China

This session highlights country case studies to showcase

how pharma representatives plan their access strategies in

different countries

PANEL DISCUSSIONOvercoming registration and submission challenges in pan-Asia clinical studies• What has changed since last

year’s meeting?• How can RA representatives

be more effective in navigating through the fragmented SEA market?

• Exploring the possibility of using an adaptive regulatory submission system, customised from established markets

• Established vs. emerging markets in Asia

Faridah Aryani, Senior Principal Assistant Director, Pharmaceutical Services Division, Ministry of Health, Malaysia

Promoting regulatory innovation in Singapore and the rest of Asia• Understanding the need

for creating a simplified, innovative regulatory framework to support the exponentially-growing number of trials in Asia

• Strategies for improving regulatory expertise and cross-nation support for promoting regulatory policy innovation

• Discussing methods to remove or reduce regulatory complexity, and minimise the impact of regulatory diversity, to ensure timely access to safe, high quality therapeutic products

Overcoming regulatory restrictions in implementing new biomanufacturing processes• Understanding the regulatory

requirements for modifying bioproduction processes in their respective countries

• Discussing strategies for speeding up approval procedures to upgrade bioprocesses

• Is it worth the time and resources to upgrade existing manufacturing processing to continuous systems?

Process development preparation for effective technology transfer and operation• From R&D to manufacturing

operations, what are the considerations required to ensure smooth transfer?

• Evaluating critical aspects to evaluate to ensure event free manufacturing

• Discovering the importance of cross function communication to promote successful routine bioproduction

From clone to pilot plant scale up: Case study of developing a CHO cell culture platform for antibody productionThis presentation will explore steps in upscaling antibody production from clone to manufacturing scale, including process development, tech transfer and quality measurements

Improving supply chain agility with late stage customisation• Formulating strategies to

ensure optimal process flow • Exploring various options

to satisfy segmentation requirements with variable volumes and packaging needs

• Using late stage customisation to overcome country specific regulations and requirements

What’s next after 2D track and trace in supply chain security?• Strategies for preventing

counterfeiting • Overcoming existing

infrastructure limitations to fully utilise the potential of 2D barcoding in track and trace

• Exploring the possibility of using internet of things and smart sensing to build a more efficient supply chain

Innovate cargo monitoring and tracking for pharmaceutical products with IoT• Understanding the

infrastructure requirements for using IoT for supply chain in Asia

• Balancing cost and benefits in using IoT to ensure quality of products delivered

• Case study in Asia: Strides

14:20

14:40

15:00

THERAPEUTIC VACCINES COUNTRY SPOTLIGHTS REGULATORY AFFAIRSPROCESS DESIGN AND

DEVELOPMENT TECHNOLOGY

12:50 EXHIBITION VISIT & NETWORKING LUNCH

ROUNDTABLE DISCUSSION SESSION

DAY 1 WEDNESDAY, 22ND MARCH 2017 4/4

IPR in biosimilars development-opportunities and threats to innovation driven pharma• How do pharma companies

decide to go or not to go ahead with launching biosimilar products?

• How do pharma companies leverage on Asia landscape to maximise revenue?

• Should biosimilar industry be worried over AbbVie’s IPR success case vs Amgen in the US?

Conquering future challenges by strategic positioning of downstream processing With the aim of providing wider treatment access, new classes of therapeutic drugs with greater specifity and higher potency need to be manufactured, and in a flexible volume to cater to the needs of the population. This session will explore potential solutions for making drugs more ‘manufacturable’ from a downstream perspective.

Streamlining supply chain with Big Data• Discover how big data can

help you handle your supply chain more easily in Asia

• Understanding the benefits of using cloud, data and analytics to drive operational efficiencies

• Overcoming challenges in real time transmission of data into cloud storage

15:20

THERAPEUTIC VACCINES COUNTRY SPOTLIGHTS REGULATORY AFFAIRSPROCESS DESIGN AND

DEVELOPMENT TECHNOLOGY

15:40

16:20




Table 1Countries specific strategies in overcoming challenging green field regulatory landscape

Table 2Performance based reimbursement- Why and how can we do that?

Table 5Maximising production output: Quality approach

Table 9IPR and patent related issues in biosimilars development

Table 10Building sustainable innovation ecosystem in Asia

Table 3Globalizing Clinical Trial Operations – Asia’s emerging leadership roleRobert Bruno, Director, Japan Clinical Operations, AbbVie, Japan

Table 4Talent management and communication strategies in pharma landscape

Table 7Key considerations in implementing continuous single use platform in Asia production

Table 8IoT in pharma supply: Where are we now and what’s next?

Table 11Finding licensing and supply chain partner in Asia developing economy

Table 12Partnership models for biotech startup

Country update:

Indonesia

Country update:

Vietnam

17:40 NETWORKING DRINKS RECEPTION

ASIA SPOTLIGHT: CREDIBILITY & PATIENT CENTRICITY

17:00 Overcoming credibility issues in Asia clinical trials and manufacturing processesWith two third of world’s population residing in Asia, it is unsurprising that Asia is the next market where biopharma are investing to grow. However, plagued with scandals and quality issues, many small to mid-size overseas companies are hesitating to enter the value chain here. In this presentation, we explore how stakeholders in Asia can work together to produce higher quality results and products to regain global confidence in the region.

17:20 Keeping patient centricity as an intrinsic goal in Asia pharmaceutical companiesEveryone wants to be a part of the lucrative Asia pharma market, but how do we make sure that our company is innovative enough to keep out competitors, while keeping patients’ interest as the ultimate objective to deliver health and healing? In this session, we explore how you can use a patient centricity approach to differentiate your business operation from your competitors.

Table 6Strategies to overcome production challenges when starting new manufacturing project in AsiaShao Siong Chua, Production Lead (Site Expansion), BioProduction Operations, Novartis, Singapore

DAY 2 THURSDAY, 23RD MARCH 2017 1/4

ANTIBODY DRUG CONJUGATES AND DERIVATIVES

BIOTECHINNOVATION

This exciting new addition to BioPharma Asia 2017 will see 40 of Asia’s most

exciting and innovative biotechs offering 10-minute insights into their

products, pipelines and their pathway to commercialization.

Company presentation-Immunwork

Tse Wen Chang, Founder, Immunwork, Taiwan




Medical led stakeholder engagement: How can drug providers better interact with patients and healthcare professionals in Asia?• How can pharma providers better

engage patients and investigators by setting aside investigator led funding, education grant and trial grant bonds for quality studies?

• Discovering strategies in making patients the priority in medical communication

• Exploring options to provide support, sponsorship and resources to patient groups and care givers

Payer, policy maker and provider engagement• Exploring key relationship building

strategy in working with payers and policy makers

• Understanding the concerns and priorities of stakeholders when building relationships with the national guideline committees

• Country case studies: How to successfully engage stakeholders for medical studies and drug reimbursement conversations

Digitalising healthcare practices in clinical operations• Using cloud, analytics, and electronic

source to fast track studies and potentially even approval processes

• Redefining SOP in clinical operations to integrate technology into practices

• Discovering strategic plans to train staff in moving towards digitalised practices

Enabling remote monitoring in clinical studies• Discussing possible benefits in using

advanced sensing technology for off-site patient monitoring

• Understanding technology available in providing personalised care for patients

• Overcoming challenges to widely implement remote monitoring in Asian clinical studies

Using QbD as the core design principle in continuous processing• Overcoming regulatory uncertainties in

using continuous processing • Does continuous manufacturing really

help to reduce drug development and commercialisation costs?

• Navigating regulatory guidelines

Identifying production control attributes in upgrading batch to continuous bioproduction• Understanding the best design

principles to ensure a consistent flow of products

• Integrating robust process controls and monitoring systems in continuous design

• Adopting analytical technologies and mathematical modelling to facilitate the adoption of continuous processing

From evidence generation to scientific exchange and stakeholder

management, the role of medical affairs is comprehensive and increasingly important, as they bridge the gap

between R&D and commercial. This track allows medical affairs professional to

interact and share best practices to better engage key stakeholders in Asia

MEDICAL AFFAIRS

STAKEHOLDER ENGAGEMENT

From clinical development, operations and supply to regulatory affairs, explore the latest innovations and strategies for

getting your clinical trials right.

CLINICALTRIALS

CLINICAL INNOVATIONS

Explore best practice strategies for your manufacturing activities including process design, development & implementation, and the manufacturing of high quality

emerging therapeutic products


CONTINUOUSPROCESSING

10:30

11:15

11:35

09:10

DIGITAL TRANSFORMATION IN BIOPHARAMA

From ideas to international success: A real breakthrough story brought to you by an Asian biotech company Starting from nothing to million dollar success, this biotech company currently employs thousands to benefit the healthcare industry. Hear from true blue biotech company in Asia on their success story in building the reach of their companies from domestic to international market

10:10 Strategies in providing affordable healthcare in developing countriesDeveloping countries are facing enormous challenges when it comes to dedicating natural funds and resources. In the dilemma between investing on more economy boasting industries, and providing better healthcare infrastructure and facilities for the people, the former often get more attention to promote overall growth of the country. In Asia, many countries depend on out-of-pocket to fund healthcare policies, the big question is, how can stakeholders work together in providing accessible and affordable healthcare in limited funding by the government and people to afford these services?

09:30 KEYNOTE PANEL: Big pharma perspective in driving Asia biopharma innovationWith the highest amount of resources which can be invested into operation, big pharma companies are in the best position to lead the industry direction. When making a key decision, it is important to understand the impact in organisation and industry wide. How can big pharma avoid being “too-big-to-fail” and lead the industry to be more innovative?



INFECTIOUS DISEASESEVIDENCE AND DECISION

MAKINGCLINICAL SUPPLY QUALITY & SAFETY




Company presentationOrally-delivered antiviral protein for Dengue and Zika

Eng Hung Ung, CTO, BioValence, Malaysia





The patient advocate perspective: Working better with pharma and key stakeholders to provide better patient care• Exploring various working strategies

in pre-clinical execution phase collaboration to promote disease awareness

• Working with patient groups to deliver better treatment outcomes, i.e. creating patient registry for drug trial recruitment and outreach

• Understanding potential collaboration and partnership opportunities between pharma, patient advocacy groups and government units

From pre- to post- launch: Improving the role of medical affairs in product life cycle management• Understanding the different roles

of medical affairs personnel in reimbursed market

• Exploring how medical affairs personnel help in pharma marketing

• From design, execution and supporting investigator initiated studies, how can medical affairs better utilise the available clinical outcomes to convince stakeholders in reimbursement decisions?

Prabhuram Krishnan, Medical Director (South ASEAN) and Regional Medical Advisor (Oncology), Eli Lilly, Malaysia

Using evidence-based discussions to build pharma reputation and brand recognition• Discovering strategies to further

develop and translate worldwide evidence base for local applications

• Improving uniformity and consistency in local investigator led studies

• Navigating policy intervention in scientific, evidence based decision making processes

Generating real world evidence in APAC- key challenges and strategies• Discovering strategies to generate

real-world evidence with limited resources and infrastructure

• Understanding how data collected helps in supporting market access mission of medical affairs

• Using country-by-country approach to tailor strategies in decision making

Integrating emerging technology into an effective adverse reporting process• Understanding how improving current

legislation helps to improve medical communication with patients and physicians

• Exploring the benefits in keeping up to cloud technology and social media

• Discovering how pharma companies can leverage on latest technology to reduce drug misinformation

Innovation in action: Using remote sensing and IoT for stroke patient monitoring• Using IoT for real time patient

monitoring• Discussing infrastructure limitation and

potential solutions in overcoming these challenges

• Sharing case studies on using remote sensing for patient monitoring off-sites

The impact of globalisation on clinical supply in Asia • Overview of the diverse import/export

regulatory barriers for pan-Asia clinical trials operation and supply

• Working with CROs to implement best practices in clinical supply

• Showcasing economic value to local regulators to innovate clinical supply practices

Technology integration for end-to-end clinical supply• From drug ordering to inventory

management and product distribution, how can clinical operators simplify E2E clinical supply in Asia?

• Centralised vs country specialised: What is the best clinical supply structure for diversified Asia regulatory framework?

• Exploring how clinical data management helps in improving quality and accuracy of clinical logistics and delivery

Drawing the parallel between small and large molecules: What can we learn from our industry peers?• Understanding the requirements of

continuous bioprocessing• What can biologics manufacturing

learn from small molecules and formulations team to continuously process biological products

Continuous processing in Asia: A case study• What are the added benefits in

adopting continuous processing?• Compared to conventional

biomanufacturing, what are the additional precautions required for successful implementation?

• Moving forward, what’s next after continuous processing?

QbD and beyond- where are we now in Asia?• In some countries, QbD has been

listed as one of the requirements in the submission for approval. What is the status in Asia and how can manufacturers continuously innovate to improve production cost and quality?

• Identifying critical process parameters and critical quality attributes to ensure robust technology transfer

Ensuring excellent production quality of emerging therapeutic products• Discover GMP and cGMP guidelines in

manufacturing of novel biologics, i.e. biosimilars, in Asia

• Vendor selection and management: How do we measure the quality success of our vendors?

• China case study

11:55

12:15

13:50

12:35 EXHIBITION VISIT & NETWORKING LUNCH

14:10


INFECTIOUS DISEASESEVIDENCE AND DECISION

MAKINGCLINICAL SUPPLY QUALITY & SAFETY





Adopting HEOR to balance short-term goals and long-term market access goals• Using HEOR to convince healthcare

authorities on drug functions and value• Key strategies for presenting

collected medical research data and demonstrate drugs value

• Discover the importance of HEOR in countries without a reimbursement framework

Key performance indicators in measuring the success of HEOR• How can companies prioritise HEOR

spending to best impact payers’ pricing decisions?

• Balancing financial and manpower investments to maximise the output of resources invested

• Promoting proper data analysis throughout the drug development process to ensure accurate communication with stakeholders

Clinical supply for rare disease studies• Clinical development plans in

supplying for rare disease studies• Discussing possible solutions for

minimising operational cost for orphan drugs investigation

• From patient recruitment to clinical supply, how CROs, pharma, patient groups and clinical supplier helps to promote orphan drugs development in Asia at potential minimal cost?

Improving clinical transparency, efficiency and visibility in clinical supply• Souring reliable clinical supply partners

in Asia • Discussing strategies for more

transparent financial assessment when working with hospitals and site administrators

• Building proper infrastructure support to improve clinical supply efficiency

Quality assurance and control requirements for cell therapy products• From facilities to equipment and

material, how do manufacturers make sure that cell therapy products are manufactured in well-controlled manner?

• Exploring how a risk-based approach helps in biomanufacturing QA measurements

• Deriving quality measurements to ensure compliance in upscaling from clinical stage

Optimising product and process parameters with Design of Experiment (DoE)• Using DoE as a compliment to QbD• Developing critical quality attributes in

process monitoring and validation• Modelling approaches to gain full

benefit of DoE in satisfying quality design and development activities

14:30

14:10

PLATFORM TECHNOLOGYCOMPLIANCE & PATIENT

CENTRICITYCLINICAL OPERATIONS ANALYTICAL DEVELOPMENT





Establishing the medical affairs role as a cornerstone to build trust in pharmaceutical industry• Discovering strategies to ensure

medical compliance within institution• Exploring ways in building strong,

multi-faceted medical affairs organisation to navigate global healthcare landscape

• Case study

Cultivating patient centricity in the evolving role of medical affairs• Strategies for implementing patient

centricity frameworks within pharma companies

• Crafting patient education and engagement programs in Asia

• Emphasizing data, quality and sincerity as integral core values in medical practices

Balancing cost and efficiency in performing quality clinical operations• Staffing and training strategies to

ensure quality clinical operations• Exploring possibilities in widely

implementing risk-based monitoring• Offsetting the limitation of on-site

monitoring with risk based monitoring

Conducting quality clinical trials in China, a case studyThe Chinese government has recently reformed its healthcare structure to improve quality of clinical trials and manufacturing. Find out more about the status quo of clinical operations in China and how global companies can help in ensuring quality operation by strictly enforcing GCP and other SOP in their respective team.

Maggie Lim, Director, AP Clinical Development QA, R&D, Global Quality Assurance APAC, Japan, EM, GSK, Singapore

Developing efficient analytical techniques from product development to manufacturing• Developing high stability indicating

assays• Coping with the latest configurations,

reagents and alternatives in method validation and performance

• Exploring automation as a method for streamlining QC processes and maintaining uniformity of analytical processes

Enhancing purification and analytical techniques in bispecific biologics production• Discussing the potential application

of using 2D liquid chromatography to characterise therapeutic proteins

• Developing critical attributes for deciding on the analytical techniques to be used in bioproduction

• Case study: Bispecific antibody production

15:40

16:00

15:10 EXHIBITION VISIT & NETWORKING REFRESHMENTS

Contact Emily Chong at (65) 6322 2339 [email protected] for speaking opportunities.





Company presentation Competency and compliance training of medical staff• Establishing guidelines and structures

to promote cross functional team working and communication

• Ensuring staff to adhere to required SOPs and comply with regulations

• Strategies in training medical affairs staff to adhere to consistent, high quality standards

Encouraging investigator-led studies in Asia • Understanding how investigator led

studies encourage drug access and reduce drug price in countries

• Providing easier access to drugs to encourage investigator led studies

• Establishing better reporting system by taking account of patient’s opinions

How can big pharma lead GCP implementation to promote quality clinical research in India? Clinical trials in India have been plagued with scandals due to lack of compliance and ambiguous guidelines. While the CDSCO is renewing its policy to promote quality trials in the country, local companies need to learn from their overseas counterparts to regain international confidence in the market. Find out how big pharma in India can help in leading GCP within the country.

Is Vietnam the next China in Asia?With the increasing labour cost and lack of IP protection in China, companies are shifting their focus to its neighbour: Vietnam. Home to over 80 million population with one of the least advanced healthcare infrastructure in Asia, Vietnam poses one of the highest potential in the eye of industry. Find out how pharma companies venture and overcome barriers in conducting trials in Vietnam from this session.

Biocomparability and stability studies in biosimilar production• Key characterisation techniques to

ensure biosimilar functionality • Discussing strategies to maintain

product quality in upscaling biosimilar• Exploring key assays techniques and

development for biosimilar testing

Host cell protein (HCP) characterisation and mass spectrometry strategies• Adding mass spectrometry as part of

the host cell protein workflow• Analytical strategies in HCP

identification and purification process• Developing quantitative MS/MS

methods to determine HCP levels

16:20

16:40

17:00 CLOSE OF BIOPHARMA ASIA 2017

PLATFORM TECHNOLOGYCOMPLIANCE & PATIENT

CENTRICITYCLINICAL OPERATIONS ANALYTICAL DEVELOPMENT

SEMINAR PROGRAM WEDNESDAY, 22ND MARCH 2017DAY 1

END OF DAY 1 SCIENTIFIC SHARING END OF DAY 1 TECHNICAL UNIVERSITY

INFECTIOUS DISEASES AUTOMATION

NEUROLOGY PROCESS DESIGN

BIOMARKERS AND PLATFORM TECHNOLOGY FACILITY DESIGN

10:00 Early treatment for chronic Hepatitis B infected patients Feedback system

13:00 Neuro stem cell research Filtration system

15:30Genetic marker research assay for Alzheimer disease risk assessment

HVAC/ Humidity measurements

10:30 Overcoming challenges in treating Tuberculosis in Asia Sensing techniques

13:30 Pre-clinical candidate in treating Autism Spectrum DisorderMichael Entzeroth, Chief Operating Officer, Cennerv Pharma, Singapore

Viral removal

16:00Next generation anti-viral protein in combating global infectious diseases

Clean room design

11:00Platform technology in infectious virus vaccine development- a case study

To be announced

14:003D neuro cell culture- Self organisation of polarised cerebellar tissue in 3D culture of human pluripotent stem cell

Chromatography

16:30

RetroMAD1 – broad spectrum orally-delivered antiviral protein therapeuticRetroMAD1 is made using recombinant E.coli and easy to upscale. It has very good safety characteristics and it can withstand digestive enzymes for 2 hours. It is absorbed into the blood within 30 minutes and has a 39% bioavailability in non-human primates. It has also been tested on a variety of RNA and DNA viruses in selected in vitro and in vivo models in shrimp, fish, cats, dogs and monkeys. Among the potential human viruses of interest where testing has been carried out are Ebola, Dengue and Zika.Eng Hung Ung, CTO, BioValence, Malaysia

Cleaning validation

11:30Discovering safety and effect novel dengue vaccines in Asia children

To be announced

14:30Minimising inflammation in brain to prevent development of Alzheimer disease

Culture and media

17:00 To be announced To be announced

RESEARCH SHOWCASE MANUFACTURING TECHNOLOGY SHOWCASE

This conference track showcases early R&D in vaccines, infectious diseases and imaging technology.

This conference track showcases manufacturing and analytical techniques updates.

SEMINAR PROGRAM THURSDAY, 23RD MARCH 2017DAY 2

END OF DAY 2 SCIENTIFIC SHARING END OF DAY 2 TECHNICAL UNIVERSITY

THERAPEUTIC VACCINES RAPID TOOLS

STEM CELLS & GENE THERAPY AGGREGATIONS & STABILITY

IMAGING & DRUG DELIVERY TECHNOLOGY FACILITY DESIGN

10:00Using virus-like vesicle-based therapeutic vaccine to treat diseases

Fast method to analyse multiple attributes of therapeutic antibodies

12:30Novel biomarkers of resistance of pancreatic cancer cells to oncolytic vesicular stomatitis virus.

Simultaneous detection of protein aggregation

10:30Using therapeutic vaccines to cure HIV- is that still of an interest after many disappointments?

High throughput screening for antibodies

13:00 Biomarkers for hormone receptor for breast cancer patients Forced degradation studies

15:30Emerging characterization tools for biocomparability, test methods and specifications

Nanotechnology in precision targeting on cancerous tumour

16:00 Targeted therapy and delivery system with light and DNA cages ICH guidelines, practical examples and discussions

11:00Replicating HBV specific immune response with monocyte in developing vaccine therapy

Rapid peptide mapping

13:30 Using biomarkers for targeted therapy and rare disease treatment Residual quantification with NMR

15:00

T-ETM pharmaceutical molecules with both targeting and effector functions for improved efficacy and safetyImmunwork develops T-ETM molecules containing both targeting (T) and effector (E) moieties for applications in cancer, autoimmune, infectious, and CNS diseases. The T and E modules, which are based on multi-arm linker units, are constructed separately and then joined together by click chemistry. Our T-ETM platform can produce ADCs with improved DAR, homogeneity, and manufacturing processes, and also bispecific and multi-specific antibodies with optimal valency of T and E elements.Tse Wen Chang, Founder, Immunwork, Taiwan

Defining critical quality attributes, control strategies and change management

11:30Novel vaccination strategy to leverage on mucosal immunity and induction of mucosal immune response in treating HPV infection

Low concentration dosage analysis

14:00 Using stem cell therapy to combat chronic infectious diseases To be announced

16:30 To be announced To be announced

RESEARCH SHOWCASE MANUFACTURING TECHNOLOGY SHOWCASE

This conference track showcases early R&D in vaccines, infectious diseases and imaging technology.

This conference track showcases manufacturing and analytical techniques updates.

To get involved in the conference programme, contact Pinky Fadullon at (65) 6322 2738 or [email protected]

• CEO, CSO, and Head of BD from Asian biotechs

• Researchers & Scientists from universities

• Head of BD and R&D from pharma

• VCs and PEs

• Senior market analysts from big banks

INNOVATION & PARTNERING

• Process Engineers

• Supervisors

• Investigators

MANUFACTURING TECHNOLOGY SHOWCASE

• Researchers

• Professors / PhDs

• Scientists

• Principal investigators

RESEARCH & DEVELOPMENT

• Researchers

• Professors / PhDs

• Scientists

• Principal investigators

SUPPLY CHAIN & LOGISTICS

• Clinical Trial Managers

• Clinical Supply Chain Managers

• Clinical Outsourcing Managers

• Heads of R&D from Pharmas

CLINICAL TRIALS

• Heads of Upstream

• Heads of Downstream

• Process Engineers from Pharmas and Biotechs

• Heads of Manufacturing

• Heads of Operations


• Departments and Ministries of Health

• Heads of Market Access / Pricing & Reimbursement

• Heads of Commericalisation

• Chiefs/VPs of Medical

• Medical officers

COMMERCIALIZATION &MEDICAL AFFAIRS

Attendee profile

USA

Europe

Australia & New Zealand

India & Middle East

Southeast Asia• Singapore

• Malaysia

• Thailand

• Indonesia

• Philippines

• Vietnam

North Asia• Japan

• Korea

• China

• Hong Kong

• Taiwan

10%

3%60%

2%

18%

7%

Contact Pinky Fadullon at (65) 6322 2738 or [email protected] to discuss your participation optionsWho attends

SERVICE DRIVEWAY

ENTRANCE/EXIT

MTech

RESEARCHSHOWCASE

NETWORKING

BIOTECHINNOVATION

CLINICALTRIALS

BioMANUFACTURING

LUNCH

C02 D02B02

A06

B12

A09

A07

A05

A02

B08

D10

D14

D26

D18

D08

D12

E08

E12

C13

E16 F15

F06

F10

F08

F12

F14

F22

D21

D15

D20 E19

F24

D23

D17

D22 E21

F26

D25

D19

D24 E23

A04

B10

B03

C09

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

POD

PODPOD

PODPOD

PODPOD

PODPOD

PODPOD

PODPOD

PODPOD

PODPOD

PODPOD

PODPOD

Supply Chain

Manufacturing

Clinical Trials

Market access & Medical Affairs

Biotech Innovation Showcase

EXHIBITION

Contact Pinky Fadullon at (65) 6322 2738 [email protected] to discuss your participation options

Escalators Lift Restrooms

• Investment banks/investment advisers

• M&A legal consultants

• Laboratory supplies & services

• Platform technology

• Drug delivery technologies

• Medical device and diagnostics companies

• Raw materials, ingredients and APIs

INNOVATION & PARTNERING

• Bioprocess solutions

• Single Use

MANUFACTURING TECHNOLOGY SHOWCASE

• Mass spectrometry

• Chromatography

• Lab equipment and technologies

• Lab services

• Consumables

RESEARCH & DEVELOPMENT

• Cold chain and logistics providers

• Express logistics providers

• Packaging

• 3 PL

• Warehouses

• Software technologies

• Forwarding

SUPPLY CHAIN & LOGISTICS

• CROs

• Clinical trial sites

• Regulatory Consultants

• Translation consultants

• Small-scale logistics & transportation

• Tools and equipment

• Forecasting

• Clinical supply chain and logistics

• Express logistics

CLINICAL TRIALS

• CMO

• Logistics & transportation

• EQM & Tools

• EQM distributors

• Culture media, sera and reagents

• Engineering companies and contractors

BIO-MANUFACTURING AND MANUFACTURING TECHNOLOGY

• Pricing & Reimbursement Experts

• Commercialization experts

• Forecasters

• Healthcare communication consultants

• Ad agencies

• Marketing/Medical affairs consultants

• Wholesale and retail pharmacies/distributors

COMMERCIALIZATION &MEDICAL AFFAIRS

Exhibition Opportunities

Available Booked/Reserved

Contact Pinky Fadullon at(65) 6322 2738 or

[email protected] to discuss your

participation options

Partner with us 10ways to engage clients

EXHIBIT

Showcase your solutions and technology to over 2000 Asia’s leading bipharma industry leaders by taking a stand on the exhibition floor. Maximize your brand visibility by taking a stand at a prime location.

COCKTAIL RECEPTION

Maximize your networking opportunities by hosting the cocktail reception. Increase your brand exposure during the exclusive cocktail reception to attendees across verticals and regions.

LEAD GENERATION

This is a digital inbound marketing program that uses social marketing and CRM to create awareness for your product or services. It allows you to generate leads that you can add to your sales pipeline.

CASE STUDY PRESENTATIONS

Deliver your brand message and demonstrate your thought leadership on a chosen topic to your target audience, all gathered in one room.

AWARDS

Present an award to recognize your buyers for their contribution to the industry and be seen as the leading solution provider in your field.

WORKSHOPS

Host an exclusive workshop on a topic chosen by you for prequalified biopharma leaders. Engage your current clients and leave it up to us to promote this to your prospects!

ARRANGED MEETINGS

Let us reach out to your prospects and help you arrange private meetings on-site!

ROUNDTABLE DISCUSSIONS

Host a roundtable of up to 20 industry professionals around a key topic. The format is a really powerful forum to meet qualified, self-selected attendees to debate a problem they have, that you can solve.

BRAND AWARENESS

This event is already being marketed by us. The sooner you join the more exposure you will get, via our website and other digital channels, print media and online community. Associate your brand with Asia’s leading bipharma gathering, and place it alongside or even more prominently than your competitors’.

PANEL DISCUSSIONS

Sit alongside the biopharma industry leaders to discuss key challenges of the market on one of our panel discussions. There is no other opportunity as suitable to present how well your solutions can be adopted.

Benefits

Keynote Presentation

Conference Panel

Exhibition Presentation

Conference Track

1-to-1 Meetings

Private Luncheon

Workshop / Site Tour

Keynote Panel

Client Pass

Conference Roundtable

Lanyard/Conference bag

Conference Presentation

Exhibition Booth

Conference Pass

Cocktail Reception

Exhibition space

Title

Day 1 Morning

1 Panelist

1 Presentation

1 Track

15 Meetings

Yes

1 Panelist

20 Passes

1 Discussion

Yes

1 Presentation

72 sqm

15 Passes

$400 / sqm

Workshop or

Cocktail

1 Presentation

Yes

5 Passes

18 sqm

3 Passes

Yes

Associate

1 Presentation

2 Passes

1 Discussion

12 sqm

2 Passes

Silver

1 Panelist

1 Presentation

5 Passes

18 sqm

3 Passes

Gold

1 Presentation

3 Meetings

8 Passes

1 Presentation

24 sqm

5 Passes

Platinum

1 Panelist

1 Presentation

1 Track

7 Meetings

1 Panelist

10 Passes

1 Discussion

1 Presentation

36 sqm

8 Passes

Diamond

Day 2 Morning

1 Panelist

1 Presentation

1 Track

10 Meetings

Yes

1 Panelist

15 Passes

1 Discussion

1 Presentation

54 sqm

10 Passes

Diamond Sponsor

Exhibitors

Silver Sponsor

Associate Sponsor

2017 sponsors & exhibitors

The earlier you book, the more you’ll save.Your next step towards building an effective presence at the event begins now.

Contact Pinky Fadullon at (65) 6322 2738 or [email protected]

Documents

Innovation. Commercialisation. Access · Innovation. Commercialisation. Access AGENDA ANNOUNCED 40+ COUNTRIES 2 ... Jim Miller Vice President and ... Stephen Dunn Regional Director